HEPHAISTOS-Pharma
Hephaïstos Pharma is a biopharmaceutical company developing HEPHA440, a third-generation TLR4 agonist small-molecule designed to boost innate immunity. The drug candidate aims to convert myeloid-rich, immunotherapy-resistant tumors into responsive ones by remodeling the tumor microenvironment. The company targets cancer patients who fail to derive durable benefit from current treatments, with clinical trials scheduled to begin in 2027.
Visit websiteOrsay, France
Biotechnology
Biopharmaceuticals
Oncology
Immunotherapy
Funding summary
- Total raised
- €4.3M
- Funding rounds
- 1
Investors in HEPHAISTOS-Pharma
Investors on record for HEPHAISTOS-Pharma. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like HEPHAISTOS-Pharma?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors